Use of MEK inhibitors in treating abnormal cell growth
AssigneeAgouron Pharmaceuticals, Inc.
InventorsMark Meyer, Samuel DePrimo, Judith Leopold, Seth Sadis, Matthew Spear, Weiwei Tan, Lloyd Whitfield
Life of this patent
Estimating the term…
Abstract
This invention relates to use of the compound N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide for treating abnormal cell growth in mammals. In particular, the invention provides dosage regimes for administration of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to mammals suffering from cancer.
Claims16
A dosage form for administration to a human suffering from abnormal cell growth in a body tissue, the dosage form comprising N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, a pharmaceutically acceptable salt or solvate, or a mixture thereof, in an amount effective to reduce phosphorylation of ERK in the body tissue by at least 50%.
A dosage form for administration to a human suffering from abnormal cell growth in a body tissue, the dosage form comprising N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, a pharmaceutically acceptable salt or solvate, or a mixture thereof, in an amount effective to suppress a proliferation marker Ki67 in the body tissue by at least 30%.
A combination, consisting essentially of N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof, and N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
Dependencies are inferred from the claim text.